List view / Grid view

Hepatitis C (HCV)

 

AbbVie receives CHMP positive opinion for Hep C tablet combination

2 March 2017 | By Niamh Marriott, Digital Editor

The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for Abbvie’s shorter, eight-week treatment of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) as an option for previously untreated adult patients with geotype 1b chronic hepatitis C virus (HCV)…

H is for Hepatitis C

23 November 2016 | By Niamh Louise Marriott, Digital Content Producer

H is for Hepatitis C - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest in Hep C research...

MSD’s Hepatitis C drug given green light for EU market

9 August 2016 | By MSD

Following successful phase 3 clinical trials, in which MSD’s new Hepatitis C drug, Zepatier, performed well, achieving high virologic cure rates across the study, the European Commission has licensed the drug for sale in the European market, specifically for the treatment of chronic hepatitis C virus (HCV) in adults with…

Hepatitis C: commitment to a cure

28 July 2016 | By Niamh Louise Marriott, Digital Content Producer

To find out more about Hepititis C, European Pharmaceutical Review spoke with Raquel Peck, CEO of the World Hepatitis Alliance and discovered exactly what it is being done to combat this widespread global health issue...